ZFGN Zafgen Inc.

0.79
0  -0%
Previous Close 0.79
Open 0.83
Price To Book 0.55
Market Cap 29,698,402
Shares 37,469,596
Volume 110,416
Short Ratio
Av. Daily Volume 184,514
Stock charts supplied by TradingView

NewsSee all news

  1. Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results

    Zafgen and Chondrial Therapeutics previously announced a definitive merger agreement Merger creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases

  2. Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement

    Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Chondrial Therapeutics' lead asset, CTI-1601, currently being evaluated in Phase 1 clinical trial for

  3. Zafgen Reports Third Quarter 2019 Financial Results

    Evaluation of strategic alternatives ongoing BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (NASDAQ:ZFGN) today reported its third quarter 2019 financial results. In September 2019, Zafgen announced plans

  4. Zafgen to Explore Strategic Alternatives

    BOSTON, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (NASDAQ:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Data from in vivo animal model unlikely to resolve current clinical hold - September 5, 2019.
ZGN-1061
Diabetes
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity
Announced July 2016 suspension of development of Beloranib
Beloranib
Prader-Willi Syndrome (PWS)
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity
Phase 1 data due by the end of 2020.
CTI-1601
Friedreich’s ataxia (FA)

Latest News

  1. Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results

    Zafgen and Chondrial Therapeutics previously announced a definitive merger agreement Merger creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases

  2. Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement

    Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Chondrial Therapeutics' lead asset, CTI-1601, currently being evaluated in Phase 1 clinical trial for

  3. Zafgen Reports Third Quarter 2019 Financial Results

    Evaluation of strategic alternatives ongoing BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (NASDAQ:ZFGN) today reported its third quarter 2019 financial results. In September 2019, Zafgen announced plans

  4. Zafgen to Explore Strategic Alternatives

    BOSTON, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (NASDAQ:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients